Author: Akhmetova Aigerim
Editor: Merentsova Anastasia
Darolutamide is an oral androgen receptor inhibitor with an innovative chemical structure that binds to receptors with high affinity (strength of interaction) and exhibits strong antagonistic (weakening) activity.
This was a double-blind, placebo-controlled study. 1509 men were randomly assigned in a 2: 1 ratio to receive darolutamide (955 patients) or placebo (554 patients). After the results of the initial analysis were considered positive in patients in the placebo group, the authors of the study allowed the latter to switch to darolutamide treatment.
According to the results of the study, the average observation time was 29.0 months. The overall survival rate after 3 years was 83%. The risk of death was significantly lower - 31% - in the darolutamide group compared to the placebo group.
According to scientists, this drug may become a breakthrough in the treatment of non-metastatic castration-resistant prostate cancer, and therefore increase the duration and quality of life of people with this diagnosis.
Source: https://pubmed.ncbi.nlm.nih.gov/32905676/
